Life Changing Developments in ADCs Benefiting Patients
According to the new report by RNCOS entitled, "Global Antibody Drug Conjugate Market Outlook 2020", there have been significant developments in the ADC segment. Some of these developments are the increased use of ADCs for the treatment of hematological malignancies. Recently, Seattle Genetics and Bristol Mayer Squibb have collaborated to evaluate Adcetris and Opdivo combination in two planned Phase 1/2 clinical trials for the treatment of hematological malignancies. Also, a novel antibody–drug conjugate has been developed by researchers at Igenica...
View full press release